Therapeutic Goods Administration Adj. Professor John...

Therapeutic Goods Administration Adj. Professor John Skerritt's interview on ABC News Breakfast recently.

excerpt regarding Novavax...

MICHAEL ROWLAND:         

Okay. So our suite of vaccines now is Pfizer, AZ obviously, now Moderna. So Novavax is next on the list. How far is that away?

JOHN SKERRITT:                 

It's coming. They are still working on manufacture [audio skips] large scale up. And it will be September, before they give us the rest of the data. It's important to know that we are able to look at data as it comes in. So we've already looked at a lot of Novavax data and it looks good. But the critical issue is manufacturing enough to meet all the demand. That's why the announcement of Moderna was so important, but we do expect Novavax to come along in the months to come.